US4163058A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof
Assignee: Interx Research Corp
•
Filing: 1977-04-22
•
Granted: 1979-07-31
•
Expires: 1997-04-22
Abstract
Abstract Novel derivatives of 5,5-diphenylhydantoin, having the formula: ##STR1## wherein R is as defined in the specification and claims hereinafter, are disclosed. These compounds exhibit enhanced solubility over diphenylhydantoin per se and find therapeutic usefulness as anticonvulsants, antiepileptics and antiarrhythmics.
Inventors
- 👤 Valentino J. Stella
- 👤 Kenneth B. Sloan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 13:34
CPC Classifications
C; C07; C07D; C07D233/00; C07D233/54; C07D233/66; C07D233/72; C07F; C07F9/00; C07F9/02; C07F9/547; C07F9/645; C07F9/6503; C07F9/6506
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
100 words
A 5,5-diphenylhydantoin compound having the formula: ##STR12## wherein R represents H or a member selected from the group consisting of ##STR13## wherein R 1 represents a member selected from the group consisting of H and C 1 -C 7 straight or branched alkyl; wherein X is --O-- or --S--; and wherein R 2 represents ##STR14## wherein R 4 is an acyl residue of any naturally occurring protein amino acid; with the proviso that R in both occurrences cannot represent H simultaneously; or the pharmaceutically acceptable acid addition or basic salts, C 1 -C 4 alkylhalide quaternary salts or N-oxide thereof.
Claim 2
Dependent Claim
100 words
A 5,5-diphenylhydantoin compound having the formula: ##STR12## wherein R represents H or a member selected from the group consisting of ##STR13## wherein R 1 represents a member selected from the group consisting of H and C 1 -C 7 straight or branched alkyl; wherein X is --O-- or --S--; and wherein R 2 represents ##STR14## wherein R 4 is an acyl residue of any naturally occurring protein amino acid; with the proviso that R in both occurrences cannot represent H simultaneously; or the pharmaceutically acceptable acid addition or basic salts, C 1 -C 4 alkylhalide quaternary salts or N-oxide thereof.
Claim 3
Dependent Claim
6 words
The compound of claim 1: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin.
Claim 4
Dependent Claim
7 words
The compound of claim 1: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin methanesulfonate.
Claim 5
Dependent Claim
7 words
The compound of claim 1: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin salicylate.
Claim 6
Dependent Claim
120 words
A pharmaceutical composition comprising an effective anticonvulsant, antiepileptic or antiarrythmic amount of a 5,5-diphenylhydantoin compound having the formula: ##STR15## wherein R represents H or a member selected from the group consisting of ##STR16## wherein R 1 represents a member selected from the group consisting of H and C 1 -C 7 straight or branched alkyl; wherein X is --O-- or --S--; and wherein R 2 represents ##STR17## wherein R 4 is an acyl residue of any naturally occurring protein amino acid; with the proviso that R is both occurrences cannot represent H simultaneously; or the pharmaceutically acceptable acid addition or basic salts; C 1 -C 4 alkylhalide quaternary salts or N-oxide thereof in combination with a pharmaceutically acceptable inert carrier.
Claim 7
Dependent Claim
120 words
A pharmaceutical composition comprising an effective anticonvulsant, antiepileptic or antiarrythmic amount of a 5,5-diphenylhydantoin compound having the formula: ##STR15## wherein R represents H or a member selected from the group consisting of ##STR16## wherein R 1 represents a member selected from the group consisting of H and C 1 -C 7 straight or branched alkyl; wherein X is --O-- or --S--; and wherein R 2 represents ##STR17## wherein R 4 is an acyl residue of any naturally occurring protein amino acid; with the proviso that R is both occurrences cannot represent H simultaneously; or the pharmaceutically acceptable acid addition or basic salts; C 1 -C 4 alkylhalide quaternary salts or N-oxide thereof in combination with a pharmaceutically acceptable inert carrier.
Claim 8
Dependent Claim
10 words
The combination of claim 5, wherein said compound is: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin.
Claim 9
Dependent Claim
11 words
The composition of claim 5, wherein said compound is: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin methanesulfonate.
Claim 10
Dependent Claim
11 words
The composition of claim 5, wherein sid compound is: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin salicylate.
Claim 11
Independent Claim
123 words
A method for alleviating cardia arrythmias or convulsions in a warm-blooded animal which comprises administering thereto, an effective antiarrythmic or anticonvulsant amount of a 5,5-diphenylhydantoin compound having the formula: ##STR18## wherein R represents H or a member selected from the group consisting of ##STR19## wherein R 1 represents a member selected from the group consisting of H or C 1 -C 7 straight or branched alkyl; wherein X is --O-- or --S--; and wherein R 2 represents ##STR20## wherein R 4 is an acyl residue of any naturally occurring protein amino acid; with the proviso that R in both occurrences cannot represent H simultaneously, or the pharmaceutically acceptable acid addition or basic salts, C 1 -C 4 alkylhalide quaternary salts or N-oxide thereof.
Claim 12
Independent Claim
123 words
A method for alleviating cardia arrythmias or convulsions in a warm-blooded animal which comprises administering thereto, an effective antiarrythmic or anticonvulsant amount of a 5,5-diphenylhydantoin compound having the formula: ##STR18## wherein R represents H or a member selected from the group consisting of ##STR19## wherein R 1 represents a member selected from the group consisting of H or C 1 -C 7 straight or branched alkyl; wherein X is --O-- or --S--; and wherein R 2 represents ##STR20## wherein R 4 is an acyl residue of any naturally occurring protein amino acid; with the proviso that R in both occurrences cannot represent H simultaneously, or the pharmaceutically acceptable acid addition or basic salts, C 1 -C 4 alkylhalide quaternary salts or N-oxide thereof.
Claim 13
Dependent Claim
18 words
The method of claim 12, wherein said compound is administered in combination with a pharmaceutically acceptable inert carrier.
Claim 14
Dependent Claim
10 words
The method of claim 9, wherein said compound is: 3-(N,N-Dimethylglycycloxymethyl)diphenylhydantoin.
Claim 15
Dependent Claim
11 words
The method of claim 9, wherein said compound is: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin methanesulfonate.
Claim 16
Dependent Claim
11 words
The method of claim 9, wherein said compound is: 3-(N,N-Dimethylglycyloxymethyl)diphenylhydantoin salicylate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-07-30 | 1983-01-29 | 1983-07-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-07-30 | 1987-01-29 | 1987-07-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-07-30 | 1991-01-29 | 1991-07-31 | $7700.00 | Window Closed / Lapsed |